Named Bioactive Compounds · Enzyme
Ficin
Moderate Evidenceenzyme2 PubMed Studies
Hermetica Superfood Encyclopedia
Ficin is a proteolytic enzyme extracted from fig latex that breaks down proteins through its cysteine protease activity. Clinical research suggests ficin may reduce eye floaters and demonstrates concentration-dependent effects on blood coagulation.
Ficin is a proteolytic enzyme extracted from the latex of fig trees (Ficus carica), particularly from varieties like Kadota. It exists in multiple molecular forms including cysteine proteases (FPI, FPII) and serine protease (FPIII), obtained through purification processes that separate these isoforms from the plant's milky latex.
Clinical evidence for ficin is limited to one double-blind RCT (n=224) testing mixed fruit enzymes (190mg bromelain, 95mg papain, 95mg ficin) for vitreous opacities, showing significant improvement versus placebo after 3 months. Most research involves laboratory applications in immunohistochemistry and blood typing rather than human health outcomes. No PMIDs were provided in the research dossier.
Clinically studied dosage: 95mg ficin daily (1 capsule) or 190mg daily (2 capsules) for 3 months, always in combination with bromelain and papain. No data exists for standalone ficin supplements or standardized activity units. Consult a healthcare provider before starting any new supplement.
Ficin is a sulfhydryl cysteine protease enzyme extracted primarily from fig latex (Ficus species, including Ficus carica, Ficus glabrata). As a purified enzyme preparation, it does not function as a conventional nutritional ingredient with meaningful macronutrient or micronutrient contributions at typical use concentrations. Key biochemical composition: Ficin is a glycoprotein with a molecular weight of approximately 23,800–26,000 Da; it contains a catalytic cysteine residue essential for proteolytic activity. The enzyme is typically supplied as a partially purified latex extract or lyophilized powder with protease activity measured in units (e.g., units/mg protein). Protein content of crude fig latex preparations ranges broadly depending on purification grade, with ficin representing a significant fraction of total soluble protein in latex. Bioactive compounds: The primary bioactive is the ficin enzyme itself, with proteolytic specificity toward fibrinogen, elastin, collagen, and casein substrates. Fig latex also contains minor cysteine proteases (ficin isoforms A, B, C, D), peroxidases, and polyphenols in crude extracts, though these are largely removed in pharmaceutical-grade preparations. Carbohydrate content: Ficin contains approximately 5–10% covalently linked carbohydrate (mannose and N-acetylglucosamine residues) as part of its glycoprotein structure. Bioavailability: As a protein enzyme, oral ficin is subject to degradation by gastric acid and pepsin, substantially limiting systemic bioavailability; enteric coating or co-formulation strategies are typically required for any intended systemic proteolytic effect. Ophthalmic or injectable preparations bypass this limitation entirely.
Ficin functions as a cysteine protease, cleaving peptide bonds at specific amino acid sequences through nucleophilic attack by its active site cysteine residue. The enzyme demonstrates bidirectional coagulation effects by activating factor XII at low concentrations while inhibiting thrombin formation at higher doses. Its proteolytic activity also breaks down fibrin deposits and enhances protein hydrolysis in the digestive system.
One randomized controlled trial (n=224) found that ficin combined with other proteolytic enzymes significantly reduced vitreous opacities (eye floaters) compared to placebo over 3 months. Laboratory studies demonstrate dose-dependent anticoagulant effects at concentrations above 0.1 mg/mL and procoagulant activity at lower doses. The evidence base remains limited with most research conducted in vitro or using enzyme combinations rather than isolated ficin. Human safety and efficacy data are insufficient to establish definitive therapeutic recommendations.
Ficin may cause allergic reactions in individuals sensitive to fig latex or related proteins, with symptoms ranging from skin irritation to anaphylaxis. The enzyme's anticoagulant properties could theoretically enhance the effects of blood-thinning medications like warfarin or heparin, though clinical interactions have not been documented. Gastrointestinal side effects including nausea and diarrhea may occur with oral supplementation. Safety during pregnancy and lactation has not been established, and ficin should be avoided in these populations.
